08:05 AM EDT, 09/08/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said phase 3 trials evaluating its investigational allergen-blocking antibodies in adults with moderate-to-severe cat or birch allergies met their primary and secondary endpoints with a "high degree of statistical significance."

In the placebo-controlled 64-patient trial for those with cat allergies, the primary endpoint of ocular itch was reduced by 52% while the secondary endpoints of conjunctival redness and skin prick reactivity were reduced by 39% and 44%, respectively, the company said.

Among 54-patient birch allergy patients, ocular itch was reduced by 51%, redness by 46%, and skin prick sensitivity by 44%, compared with the placebo, the company said.